Table 2.

Multivariate analysis of outcomes GRFS, RI, NRM, LFS, and OS using a Cox proportional hazards model for the entire cohort

P valueHR95% CI
GRFS    
HID vs MSD .9 0.99 0.9-1.21 
Age (per 10 years) .015 1.4 1.07-1.83 
Secondary AML <.0001 1.57 1.27-1.94 
Adverse cytogenetics <.0001 1.58 1.32-1.9 
KPS ≥90 .002 0.75 0.62-0.9 
Year allo-HCT 1.00 1.00 0.96-1.04 
Diagnosis to allo-HCT .07 1.03 1.00-1.06 
RIC vs MAC .49 1.09 0.86-1.37 
Female to male .053 1.21 1.00-1.46 
CMV+ patients .95 0.99 0.8-1.23 
PB vs BM .095 0.78 0.58-1.04 
RI    
HID vs MSD .003 0.62 0.45-0.86 
Age (per 10 years) .42 1.18 0.79-1.78 
Secondary AML .0007 1.7 1.25-2.3 
Adverse cytogenetics <.0001 2.24 1.72-2.91 
KPS ≥90 .089 0.79 0.59-1.04 
Year allo-HCT .66 1.01 0.96-1.07 
Diagnosis to allo-HCT .33 1.02 0.98-1.08 
RIC vs MAC .12 1.34 0.93-1.93 
Female to male .53 1.09 0.82-1.45 
CMV+ patients .3 0.85 0.63-1.15 
PB vs BM .04 0.62 0.4-0.98 
NRM    
HID vs MSD .012 1.54 1.1-2.17 
Age (per 10 years) .079 1.48 0.95-2.31 
Secondary AML .003 1.72 1.2-2.46 
Adverse cytogenetics .2 1.24 0.9-1.71 
KPS ≥90 .028 0.7 0.51-0.96 
Year allo-HCT .48 1.02 0.96-1.09 
Diagnosis to allo-HCT .57 1.01 0.96-1.07 
RIC vs MAC .79 1.05 0.72-1.55 
Female to male .4 1.15 0.83-1.59 
CMV+ patients .11 1.37 0.93-2.01 
PB vs BM .034 0.63 0.41-0.97 
LFS    
HID vs MSD .54 0.93 0.75-1.16 
Age (per 10 years) .092 1.29 0.96-1.73 
Secondary AML <.0001 1.69 1.35-2.13 
Adverse cytogenetics <.0001 1.72 1.41-2.1 
KPS ≥90 .008 0.76 0.62-0.93 
Year allo-HCT .52 1.01 0.97-1.05 
Diagnosis to allo-HCT .29 1.02 0.98-1.06 
RIC vs MAC .23 1.17 0.9-1.51 
Female to male .3 1.12 0.9-1.38 
CMV+ patients .77 1.03 0.82-1.3 
PB vs BM .002 0.62 0.46-0.84 
OS    
HID vs MSD .76 1.04 0.81-1.34 
Age (per 10 years) .023 1.47 1.05-2.04 
Secondary AML .0001 1.65 1.27-2.12 
Adverse cytogenetics <.0001 1.75 1.4-2.19 
KPS ≥90 .01 0.74 0.59-0.93 
Year allo-HCT .88 1.00 0.96-1.05 
Diagnosis to allo-HCT .75 1.01 0.97-1.05 
RIC vs MAC .11 1.28 0.95-1.74 
Female to male .17 1.18 0.93-1.49 
CMV+ patients .58 1.08 0.83-1.4 
PB vs BM .0009 0.56 0.4-0.79 
P valueHR95% CI
GRFS    
HID vs MSD .9 0.99 0.9-1.21 
Age (per 10 years) .015 1.4 1.07-1.83 
Secondary AML <.0001 1.57 1.27-1.94 
Adverse cytogenetics <.0001 1.58 1.32-1.9 
KPS ≥90 .002 0.75 0.62-0.9 
Year allo-HCT 1.00 1.00 0.96-1.04 
Diagnosis to allo-HCT .07 1.03 1.00-1.06 
RIC vs MAC .49 1.09 0.86-1.37 
Female to male .053 1.21 1.00-1.46 
CMV+ patients .95 0.99 0.8-1.23 
PB vs BM .095 0.78 0.58-1.04 
RI    
HID vs MSD .003 0.62 0.45-0.86 
Age (per 10 years) .42 1.18 0.79-1.78 
Secondary AML .0007 1.7 1.25-2.3 
Adverse cytogenetics <.0001 2.24 1.72-2.91 
KPS ≥90 .089 0.79 0.59-1.04 
Year allo-HCT .66 1.01 0.96-1.07 
Diagnosis to allo-HCT .33 1.02 0.98-1.08 
RIC vs MAC .12 1.34 0.93-1.93 
Female to male .53 1.09 0.82-1.45 
CMV+ patients .3 0.85 0.63-1.15 
PB vs BM .04 0.62 0.4-0.98 
NRM    
HID vs MSD .012 1.54 1.1-2.17 
Age (per 10 years) .079 1.48 0.95-2.31 
Secondary AML .003 1.72 1.2-2.46 
Adverse cytogenetics .2 1.24 0.9-1.71 
KPS ≥90 .028 0.7 0.51-0.96 
Year allo-HCT .48 1.02 0.96-1.09 
Diagnosis to allo-HCT .57 1.01 0.96-1.07 
RIC vs MAC .79 1.05 0.72-1.55 
Female to male .4 1.15 0.83-1.59 
CMV+ patients .11 1.37 0.93-2.01 
PB vs BM .034 0.63 0.41-0.97 
LFS    
HID vs MSD .54 0.93 0.75-1.16 
Age (per 10 years) .092 1.29 0.96-1.73 
Secondary AML <.0001 1.69 1.35-2.13 
Adverse cytogenetics <.0001 1.72 1.41-2.1 
KPS ≥90 .008 0.76 0.62-0.93 
Year allo-HCT .52 1.01 0.97-1.05 
Diagnosis to allo-HCT .29 1.02 0.98-1.06 
RIC vs MAC .23 1.17 0.9-1.51 
Female to male .3 1.12 0.9-1.38 
CMV+ patients .77 1.03 0.82-1.3 
PB vs BM .002 0.62 0.46-0.84 
OS    
HID vs MSD .76 1.04 0.81-1.34 
Age (per 10 years) .023 1.47 1.05-2.04 
Secondary AML .0001 1.65 1.27-2.12 
Adverse cytogenetics <.0001 1.75 1.4-2.19 
KPS ≥90 .01 0.74 0.59-0.93 
Year allo-HCT .88 1.00 0.96-1.05 
Diagnosis to allo-HCT .75 1.01 0.97-1.05 
RIC vs MAC .11 1.28 0.95-1.74 
Female to male .17 1.18 0.93-1.49 
CMV+ patients .58 1.08 0.83-1.4 
PB vs BM .0009 0.56 0.4-0.79 
View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal